SETD2 and lung cancer: Notably, our integrated analyses of RNA-Seq, ATAC-Seq, and ChIP-Seq data uncovered an epigenetic tumor suppressor model of SETD2 common to both kidney and lung cancers in which SETD2 loss creates a permissive epigenetic landscape for the cooperating oncogenic drivers to further amplify transcriptional output.